Elate Ocular is under clinical development by Cambium Medical Technologies and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Elate Ocular’s likelihood of approval (LoA) and phase transition for Keratoconjunctivitis Sicca (Dry Eye) took place on 25 Aug 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Elate Ocular Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Elate Ocular overview

Elate ocular is under development for the treatment of keratoconjunctivitis sicca (dry eye). It is administered as ophthalmic drops. The drug candidate is fibrinogen depleted human platelet lysate.

Cambium Medical Technologies overview

Cambium Medical Technologies (Cambium Medical) is a drug development company that develops and commercializes regenerative therapies through novel processed human platelets. It develops Elate Ocular, a pro-regenerative allogeneic human platelet derived topical ophthalmic product intended for use in treating the symptoms of chronic and corneal diseases. It also develops Aurarix, a novel processed fibrinogen-depleted human platelet lysate used for various therapeutic applications. The company’s novel platelets find applications in orthopedics, sports medicine, dermatology and maxillofacial surgery, among others. Cambium Medical is headquartered in Atlanta, Georgia, the US.

Quick View Elate Ocular LOA Data

Report Segments
  • Innovator
Drug Name
  • Elate Ocular
Administration Pathway
  • Ophthalmic
Therapeutic Areas
  • Ophthalmology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.